We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ECT Schizophrenia Serotonin Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Sha’ar Menashe Mental Health Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00278668
First Posted: January 18, 2006
Last Update Posted: May 21, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sha’ar Menashe Mental Health Center
  Purpose
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Condition Phase
Schizophrenia Phase 1

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy

Resource links provided by NLM:


Further study details as provided by Sha’ar Menashe Mental Health Center:

Estimated Enrollment: 15
Study Start Date: October 2006
Estimated Study Completion Date: October 2006
Detailed Description:
We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).

Ages 18 -55 Men and/or women -

Exclusion Criteria:

  1. History of neurological disorders, active substance abuse in the previous 3 months.
  2. Estimated IQ less then 70.
  3. SSRIs treatment 4 weeks prior to the study.
  4. Any subject suffering from inflammatory fever disease will be excluded from the study.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278668


Contacts
Contact: Avi Peled, MD 972522844050 av_peled@netvision.net.il

Sponsors and Collaborators
Sha’ar Menashe Mental Health Center
Investigators
Principal Investigator: Avi Peled, MD Shaar Menashe MHC
Principal Investigator: Ilan Modai, M.D. MHA Shaar Menashe
Principal Investigator: Moshe Rehavi, Ph.D. TAU
  More Information

ClinicalTrials.gov Identifier: NCT00278668     History of Changes
Other Study ID Numbers: 123.ctil
First Submitted: January 16, 2006
First Posted: January 18, 2006
Last Update Posted: May 21, 2008
Last Verified: May 2008

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs